Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic ar...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Rheum Dis
Main Authors: Smolen, Josef S, Mease, Philip, Tahir, Hasan, Schulze-Koops, Hendrik, de la Torre, Inmaculada, Li, Lingnan, Hojnik, Maja, Sapin, Christophe, Okada, Masato, Caporali, Roberto, Gratacós, Jordi, Goupille, Philippe, Liu Leage, Soyi, Pillai, Sreekumar, Nash, Peter
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2020
Fag:
Psoriatic Arthritis
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509529/
https://ncbi.nlm.nih.gov/pubmed/32660977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217372
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker